CLINICAL TRIALS

In a research conducted in fourteen health centres in Serbia, the compound Gastroherbal® was tested in 607 patients. 224 of them had dyspepsia, 227 flatulence, 103 gastroesophageal reflux disease, 53 had stomach ulcer.

In a research conducted in fourteen health centres in Serbia, the compound Gastroherbal® was tested in 507 patients that had some form of gastritis (superficial, atrophic, erosive) with accompanying symptoms (sickness, vomiting, reflux, loss of appetite, pain and tension, flatulence, uneasiness). The research results show that the compound Gastroherbal® has an excellent therapeutic effectiveness. The chart shows the percentage of the cured singular symptoms in various gastritis forms.

The analysis of the results has shown that complete relief and significant improvement was registered in 81, 5% of the patients with superficial gastritis, in 91, 8% of the patients with atrophic gastritis and in 81, 2% of the patients with erosive gastritis.

In a research conducted at the Institute for Digestive Tract Diseases in Shanghai, the compound Gastroherbal® was tested in 507 patients of both sexes and of the age from 17-87, who were ill with chronic gastritis.

After a month of therapy (3 capsules three times daily), Gastroherbal® was proved to be efficient in the treatment of superficial gastritis in 81,5% of the cases, in treating atrophic gastritis in 91.8 % of the cases and in the treatment of erosive gastritis in 81.2 % of the cases.

As to single symptoms, sickness disappeared with the help of Gastroherbal® in 63.7% of the cases, vomiting in 65.6%, acid reflux in 53%, loss of appetite in 68.7%, pain and tension in 59.7% of the cases, as well as dystony in the epigastrium in 77.4% of the cases.

During this study conducted by Prof. Wenzhong, the eradication of Helicobacter pylori was recorded in only 16% of the patients.

In a research conducted at the National Hospital in Qingdao in China and led by professor Zhaochung with his associates, Gastroherbal® was tested in 127 patients of both sexes, of the age between 20-75 years, who suffered from gastritis (superficial, atrophic, superficial + atrophic and superficial gastritis with bulbar inflammation).

A control group was formed with 120 patients using a comparable medication. The medication that was used for comparison was a known inhibitor of the proton pump. The percentage of convalescence was significantly higher in the group that was treated with Gastroherbal® capsules (86.9% to 70.3%).

Though, if the efficiency of these two medicaments is compared with regard to the specific manifestation of the disease, Gastroherbal® has the best efficiency in treating superficial gastritis, while a somewhat weaker effect was recorded in treating atrophic gastritis.

The clinical trial conducted by Wu Yunlin, Jiang Shihu and their associates in seven hospitals in Shanghai in China, included 102 patients with chronic gastritis.